Mallinckrodt PLC (MNK) Forecasted to Earn FY2017 Earnings of $7.20 Per Share
Mallinckrodt PLC (NYSE:MNK) – Analysts at Leerink Swann issued their FY2017 earnings estimates for Mallinckrodt in a note issued to investors on Tuesday. Leerink Swann analyst A. Fadia forecasts that the company will earn $7.20 per share for the year. Leerink Swann has a “Market Perform” rating and a $26.00 price target on the stock. Leerink Swann also issued estimates for Mallinckrodt’s Q4 2017 earnings at $1.70 EPS, FY2018 earnings at $7.20 EPS, FY2019 earnings at $7.35 EPS, FY2020 earnings at $7.50 EPS and FY2021 earnings at $6.82 EPS.
Other equities analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Mallinckrodt from a “sell” rating to a “hold” rating in a report on Tuesday, October 31st. Canaccord Genuity set a $24.00 price target on shares of Mallinckrodt and gave the stock a “hold” rating in a research report on Tuesday, November 14th. Cantor Fitzgerald set a $42.00 price target on shares of Mallinckrodt and gave the stock a “buy” rating in a research report on Tuesday, December 26th. Wells Fargo & Co restated a “hold” rating on shares of Mallinckrodt in a research report on Monday. Finally, Oppenheimer reduced their price target on shares of Mallinckrodt from $70.00 to $48.00 in a research report on Tuesday, September 19th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $45.94.
Mallinckrodt (NYSE:MNK) last released its earnings results on Tuesday, November 7th. The company reported $1.97 EPS for the quarter, topping the consensus estimate of $1.80 by $0.17. Mallinckrodt had a net margin of 11.43% and a return on equity of 14.79%. The firm had revenue of $793.90 million for the quarter, compared to the consensus estimate of $808.93 million. During the same quarter in the previous year, the firm earned $2.04 earnings per share. The company’s quarterly revenue was down 10.5% compared to the same quarter last year.
Hedge funds have recently bought and sold shares of the business. Ameriprise Financial Inc. increased its holdings in Mallinckrodt by 117.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,937,444 shares of the company’s stock worth $86,815,000 after buying an additional 1,045,757 shares during the period. Icon Advisers Inc. Co. increased its holdings in Mallinckrodt by 165.6% in the 2nd quarter. Icon Advisers Inc. Co. now owns 114,200 shares of the company’s stock worth $5,117,000 after buying an additional 71,200 shares during the period. Alliancebernstein L.P. increased its holdings in Mallinckrodt by 15.4% in the 2nd quarter. Alliancebernstein L.P. now owns 3,348,807 shares of the company’s stock worth $150,060,000 after buying an additional 448,011 shares during the period. LSV Asset Management increased its holdings in Mallinckrodt by 24.4% in the 2nd quarter. LSV Asset Management now owns 1,249,612 shares of the company’s stock worth $55,995,000 after buying an additional 244,753 shares during the period. Finally, American International Group Inc. increased its holdings in Mallinckrodt by 464.6% in the 3rd quarter. American International Group Inc. now owns 198,807 shares of the company’s stock worth $7,429,000 after buying an additional 163,596 shares during the period. Institutional investors and hedge funds own 97.35% of the company’s stock.
In other news, VP Steven J. Romano acquired 2,000 shares of the business’s stock in a transaction on Monday, November 13th. The shares were acquired at an average price of $21.96 per share, for a total transaction of $43,920.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Michael-Bryant Hicks acquired 7,900 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were purchased at an average price of $20.80 per share, for a total transaction of $164,320.00. The disclosure for this purchase can be found here. Insiders have acquired 30,460 shares of company stock worth $659,486 in the last quarter. Company insiders own 0.77% of the company’s stock.
WARNING: “Mallinckrodt PLC (MNK) Forecasted to Earn FY2017 Earnings of $7.20 Per Share” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/05/mallinckrodt-plc-mnk-forecasted-to-earn-fy2017-earnings-of-7-20-per-share.html.
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.